Skip to main content

Table 4 Efficacy endpoints

From: Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial

Variable

Group

Estimate

Standard error

95% Confidence limits

P value ANOVA/RMANOVA

P value Mann–Whitney U

Lower

Upper

Primary endpoint

       

Modified GCPS score (without B)

Robenacoxib

1.65

0.12

1.42

1.90

0.12

0.29

Meloxicam

1.97

0.18

1.63

2.35

  

Unmodified GCPS score (with B)

Robenacoxib

2.35

0.17

2.03

2.71

0.13

0.72

Meloxicam

2.79

0.26

2.31

3.34

  

Secondary endpoints

       

Pain at rest

Robenacoxib

2.62

0.31

2.06

3.28

0.20

0.54

Meloxicam

3.30

0.49

2.43

4.39

  

Pain at palpation/manipulation

Robenacoxib

4.34

0.53

3.39

5.50

0.28

0.71

Meloxicam

5.29

0.84

3.82

7.19

  

Global efficacy score

Robenacoxib

0.45

0.06

0.33

0.58

0.28

0.22

Meloxicam

0.56

0.09

0.39

0.76

  

Global inflammation score

Robenacoxib

1.11

0.25

0.66

1.67

0.12

0.59

Meloxicam

1.76

0.42

1.04

2.74

  

Owner assessment: demeanor

Robenacoxib

0.10

0.02

0.07

0.13

0.96

0.62

Meloxicam

0.10

0.02

0.06

0.14

  

Owner assessment: mobility

Robenacoxib

0.10

0.03

0.05

0.16

0.17

0.098

 

Meloxicam

0.05

0.03

-0.01

0.12

  
  1. GCPS = Glasgow Composite Pain Scale.
  2. Data are ANOVA or RMANOVA estimates for group means, standard errors and confidence intervals. P values for group comparisons are from ANOVA or RMANOVA and Mann–Whitney U tests.